logo

For the Inventor, By the Inventor

Fayetteville, NY, United States of America

James A Bush

USPTO Granted Patents = 14

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 80(Granted Patents)


Location History:

  • Fayettesville, NY (US) (1986)
  • Fayetteville, NY (US) (1977 - 1988)
  • Cheshire, CT (US) (1991)

Company Filing History:

goldMedal14 out of 637 
 
Bristol-Myers Company
 patents

Years Active: 1977-1991

Loading Chart...
14 patents (USPTO):Explore Patents
1. 5001112 - Antitumor antibiotic kedarcidin (1991-03-19),
2. 4792522 - Rigolettone antitumor complex (1988-12-20),
3. 4599310 - Process for producing antitumor antibiotic compound (1986-07-08),
4. 4598145 - Albacarcins V and M (1986-07-01),
5. 4582639 - Antitumor antibiotic compound (1986-04-15),
6. 4552842 - Process for producing rebeccamycin (1985-11-12),
7. 4487925 - Rebeccamycin and process for its preparation (1984-12-11),
8. 4461831 - Antitumor agents albacarcins V and M (1984-07-24),
9. 4360595 - Fermentation process for producing anandimycin (1982-11-23),
10. 4301248 - Fermentation process for making rachelmycin (1981-11-17),
11. 4248970 - Antibiotic complex producing bacterial culture (1981-02-03),
12. 4112071 - Antibiotic complex (1978-09-05),
13. 4064014 - Antibiotic compounds marcellomycin and musettamycin (1977-12-20),
14. 4039736 - Antibiotic compounds marcellomycin and musettamycin (1977-08-02),

Title: The Innovative Contributions of James A. Bush

Introduction

James A. Bush is a notable inventor based in Fayetteville, NY (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, he has made remarkable strides in developing antitumor antibiotics that have the potential to impact cancer treatment.

Latest Patents

Among his latest patents is the antitumor antibiotic kedarcidin. Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. This antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues. Another significant patent is the rigolettone antitumor complex. This novel complex, designated as rigolettone complex, is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.

Career Highlights

James A. Bush is currently associated with Bristol-Myers Company, where he continues to innovate and contribute to the field of cancer research. His work has been instrumental in advancing the understanding and treatment of various tumors.

Collaborations

Throughout his career, James has collaborated with esteemed colleagues, including Donald E. Nettleton, Jr. and William T. Bradner. These collaborations have further enriched his research and development efforts.

Conclusion

James A. Bush's innovative work in the development of antitumor antibiotics showcases his dedication to improving cancer treatment. His contributions are invaluable to the pharmaceutical industry and the ongoing fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…